Goat Anti-Human IgG H&L (HRP) preadsorbed (ab7153)
Key features and details
- Goat Anti-Human IgG H&L (HRP) preadsorbed
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: Dot blot, ELISA, IHC-P, IHC-Fr, WB
Overview
-
Product name
Goat Anti-Human IgG H&L (HRP) preadsorbed
See all IgG secondary antibodies -
Host species
Goat -
Target species
Human -
Specificity
Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Peroxidase, anti-Goat Serum, Human IgG and Human Serum. No reaction was observed against Bovine, Chicken, Goat, Guinea Pig, Hamster, Horse, Mouse, Rabbit, Rat and Sheep Serum Proteins. -
Tested applications
Suitable for: Dot blot, ELISA, IHC-P, IHC-Fr, WBmore details -
Minimal
cross-reactivity
Chicken, Cow, Goat, Guinea pig, Hamster, Horse, Mouse, Rabbit, Rat, Sheep more details -
Immunogen
Full length native human IgG (purified).
-
Conjugation
HRP
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 6.50
Preservative: 0.01% Gentamicin sulphate
Constituents: 0.42% Tripotassium orthophosphate, 0.87% Sodium chloride, 1% BSA -
Concentration information loading...
-
Purity
Affinity purified -
Purification notes
This product was prepared from monospecific antiserum by immunoaffinity chromatography using human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. -
Conjugation notes
Horseradish Peroxidase (HRP) -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab7153 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
Use at an assay dependent concentration.
|
|
ELISA |
1/7000 - 1/200000.
|
|
IHC-P |
Use at an assay dependent concentration.
|
|
IHC-Fr |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
Notes |
---|
Dot blot
Use at an assay dependent concentration. |
ELISA
1/7000 - 1/200000. |
IHC-P
Use at an assay dependent concentration. |
IHC-Fr
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (5)
ab7153 has been referenced in 5 publications.
- Han H et al. miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/ß-catenin signaling. Cancer Cell Int 22:42 (2022). PubMed: 35090460
- Weidenbacher PA et al. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat Chem Biol 18:1270-1276 (2022). PubMed: 36076082
- Bell BN et al. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. Protein Sci 30:716-727 (2021). PubMed: 33586288
- Uppu DSSM et al. Temporal release of a three-component protein subunit vaccine from polymer multilayers. J Control Release 317:130-141 (2020). PubMed: 31756392
- Henson D et al. Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report. Arterioscler Thromb Vasc Biol 39:1884-1892 (2019). PubMed: 31315438